CTOs on the Move

Celcuity

www.celcuity.com

 
Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.celcuity.com
  • 16305 – 36th Avenue North Suite 100
    Minneapolis, MN USA Minneapolis
  • Phone: n/a

Executives

Name Title Contact Details
David Elks
Vice President Information Technology Profile

Funding

Celcuity raised $24M on 02/24/2021

Similar Companies

Carmot Therapeutics

Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.

QuintilesIMS

Quintiles and IMSHealth have merged together to form the new QuintilesIMS. Each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. QuintilesIMS has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights.

M3 Biotechnology

M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.

Synageva BioPharma

Synageva BioPharma Corp. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keryx

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.